目的 比較不同劑量順鉑聯(lián)合吉西他濱治療非小細(xì)胞肺癌的臨床療效。方法 選取2016年2月-2018年2月復(fù)旦大學(xué)附屬中山醫(yī)院青浦分院收治的150例非小細(xì)胞肺癌患者為研究對(duì)象，按照化療藥物劑量不同，將150例患者隨機(jī)平均分為A、B、C三組，每組各50例。A組患者第1~5天每天連續(xù)靜脈輸入15 mg/m²順鉑注射液；B組患者第1~3天每天連續(xù)靜脈輸入25 mg/m²順鉑注射液；C組患者僅第1天靜脈輸入80 mg/m²順鉑注射液，3組患者均在第1天、第8天和第15天輸入1 g/m²注射用鹽酸吉西他濱，每4周為1個(gè)療程，共治療4個(gè)療程。觀察3組患者的臨床療效，比較3組治療前后血清CYFRA21-1、SCC-Ag、生活質(zhì)量評(píng)分的變化情況。結(jié)果 治療后，3組總有效率分別是32.0%、34.0%、38.0%，3組患者的總有效率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。治療后，3組患者CYFRA21-1、SCC-Ag水平均顯著下降（P<0.05），但3組患者之間比較差異無(wú)統(tǒng)計(jì)學(xué)意義?；熃Y(jié)束1周后，B組評(píng)分略有升高或降低，C組患者評(píng)分均有所下降，但A組患者的評(píng)分有所提升（P<0.05）；治療后B、C兩組生活質(zhì)量評(píng)分和A組相比差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 低劑量順鉑聯(lián)合吉西他濱治療非小細(xì)胞肺癌有較好的臨床療效，可改善患者生活質(zhì)量，小劑量順鉑連續(xù)給藥可降低患者化療的毒副反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To compare the clinical efficacy of different dosages of cisplatin combined with gemcitabine in treatment of non-small cell lung cancer. Methods A total of 150 patients with non-small cell lung cancer admitted to Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University from February 2016 to February 2018 were selected as research objects. According to different dosages of chemotherapy drugs, the 150 patients were randomly divided into A, B and C groups, with 50 patients in each group. Patients in group A were iv administered with 15 mg/m² Cisplatin Injection intravenously for 1 to 5 days. Patients in group B iv administered with 25 mg/m² Cisplatin Injection intravenously for 1 to 3 days. Patients in group C were iv administered with 80 mg/m² Cisplatin Injection only on the first day, and patients in the 3 groups were given 1 g/m² Gemcitabine Hydrochloride for injection on the 1st, 8th and 15th days. Every 4 weeks was a course of treatment, and the patients received 4 courses of treatment. The clinical efficacy of the three groups was observed, and the changes of serum CYFRA21-1, SCC-AG and life quality scores before and after treatment were compared. Results After treatment, the total effective rate of the three groups was 32.0%, 34.0%, and 38.0%, respectively, and the difference of the total effective rate among three groups was not statistically significant. After treatment, CYFRA21-1 and SCC-AG levels in the three groups were significantly decreased (P<0.05), but there was no statistically significant difference among three groups. One week after the end of chemotherapy, the life quality score of group B was slightly increased or decreased, while those of group C were decreased, but those scores of group A were improved (P<0.05). There were statistically significant differences in life quality scores among group B and Group C after treatment compared with group A (P<0.05). Conclusion Low dosage cisplatin combined with gemcitabine has good clinical efficacy in treatment of non-small cell lung cancer, and can improve the life quality of patients, and continuous administration of low dosage cisplatin can reduce the toxic and side effects of chemotherapy, which has certain clinical application value.

R978

上海市科技計(jì)劃項(xiàng)目（QKY2018-15）